125 related articles for article (PubMed ID: 21106451)
21. Potent, exceptionally selective, orally bioavailable inhibitors of TNF-alpha Converting Enzyme (TACE): novel 2-substituted-1H-benzo[d]imidazol-1-yl)methyl)benzamide P1' substituents.
Ott GR; Asakawa N; Lu Z; Anand R; Liu RQ; Covington MB; Vaddi K; Qian M; Newton RC; Christ DD; Trzaskos JM; Duan JJ
Bioorg Med Chem Lett; 2008 Mar; 18(5):1577-82. PubMed ID: 18242982
[TBL] [Abstract][Full Text] [Related]
22. Novel thiol-based TACE inhibitors: rational design, synthesis, and SAR of thiol-containing aryl sulfonamides.
Govinda Rao B; Bandarage UK; Wang T; Come JH; Perola E; Wei Y; Tian SK; Saunders JO
Bioorg Med Chem Lett; 2007 Apr; 17(8):2250-3. PubMed ID: 17289381
[TBL] [Abstract][Full Text] [Related]
23. Tumor necrosis factor alpha converting enzyme: an encouraging target for various inflammatory disorders.
Bahia MS; Silakari O
Chem Biol Drug Des; 2010 May; 75(5):415-43. PubMed ID: 20486929
[TBL] [Abstract][Full Text] [Related]
24. Identification of potent and selective TACE inhibitors via the S1 pocket.
Condon JS; Joseph-McCarthy D; Levin JI; Lombart HG; Lovering FE; Sun L; Wang W; Xu W; Zhang Y
Bioorg Med Chem Lett; 2007 Jan; 17(1):34-9. PubMed ID: 17064892
[TBL] [Abstract][Full Text] [Related]
25. Synthesis, preliminary biological evaluation and molecular modeling of some new heterocyclic inhibitors of TACE.
Sengupta P; Puri CS; Chokshi HA; Sheth CK; Midha AS; Chitturi TR; Thennati R; Murumkar PR; Yadav MR
Eur J Med Chem; 2011 Nov; 46(11):5549-55. PubMed ID: 21963348
[TBL] [Abstract][Full Text] [Related]
26. Inhibitors of TACE and Caspase-1 as anti-inflammatory drugs.
Le GT; Abbenante G
Curr Med Chem; 2005; 12(25):2963-77. PubMed ID: 16378499
[TBL] [Abstract][Full Text] [Related]
27. Identification and characterization of 4-[[4-(2-butynyloxy)phenyl]sulfonyl]-N-hydroxy-2,2-dimethyl-(3S)thiomorpholinecarboxamide (TMI-1), a novel dual tumor necrosis factor-alpha-converting enzyme/matrix metalloprotease inhibitor for the treatment of rheumatoid arthritis.
Zhang Y; Xu J; Levin J; Hegen M; Li G; Robertshaw H; Brennan F; Cummons T; Clarke D; Vansell N; Nickerson-Nutter C; Barone D; Mohler K; Black R; Skotnicki J; Gibbons J; Feldmann M; Frost P; Larsen G; Lin LL
J Pharmacol Exp Ther; 2004 Apr; 309(1):348-55. PubMed ID: 14718605
[TBL] [Abstract][Full Text] [Related]
28. Discovery and SAR of hydantoin TACE inhibitors.
Yu W; Guo Z; Orth P; Madison V; Chen L; Dai C; Feltz RJ; Girijavallabhan VM; Kim SH; Kozlowski JA; Lavey BJ; Li D; Lundell D; Niu X; Piwinski JJ; Popovici-Muller J; Rizvi R; Rosner KE; Shankar BB; Shih NY; Siddiqui MA; Sun J; Tong L; Umland S; Wong MK; Yang DY; Zhou G
Bioorg Med Chem Lett; 2010 Mar; 20(6):1877-80. PubMed ID: 20172725
[TBL] [Abstract][Full Text] [Related]
29. Novel thiol-based TACE inhibitors. Part 2: Rational design, synthesis, and SAR of thiol-containing aryl sulfones.
Bandarage UK; Wang T; Come JH; Perola E; Wei Y; Rao BG
Bioorg Med Chem Lett; 2008 Jan; 18(1):44-8. PubMed ID: 18054488
[TBL] [Abstract][Full Text] [Related]
30. 2-(2-Aminothiazol-4-yl)pyrrolidine-based tartrate diamides as potent, selective and orally bioavailable TACE inhibitors.
Dai C; Li D; Popovici-Muller J; Zhao L; Girijavallabhan VM; Rosner KE; Lavey BJ; Rizvi R; Shankar BB; Wong MK; Guo Z; Orth P; Strickland CO; Sun J; Niu X; Chen S; Kozlowski JA; Lundell DJ; Piwinski JJ; Shih NY; Siddiqui MA
Bioorg Med Chem Lett; 2011 May; 21(10):3172-6. PubMed ID: 21458257
[TBL] [Abstract][Full Text] [Related]
31. Design of selective TACE inhibitors using molecular docking studies: Synthesis and preliminary evaluation of anti-inflammatory and TACE inhibitory activity.
Sarkate AP; Murumkar PR; Lokwani DK; Kandhare AD; Bodhankar SL; Shinde DB; Bothara KG
SAR QSAR Environ Res; 2015; 26(11):905-23. PubMed ID: 26588187
[TBL] [Abstract][Full Text] [Related]
32. Structure-based rational design of peptide hydroxamic acid inhibitors to target tumor necrosis factor-α converting enzyme as potential therapeutics for hepatitis.
Wu D; Gu Q; Zhao N; Xia F; Li Z
J Drug Target; 2015 Dec; 23(10):936-42. PubMed ID: 26061299
[TBL] [Abstract][Full Text] [Related]
33. A metal-based tumour necrosis factor-alpha converting enzyme inhibitor.
Leung CH; Liu LJ; Lu L; He B; Kwong DW; Wong CY; Ma DL
Chem Commun (Camb); 2015 Mar; 51(19):3973-6. PubMed ID: 25610924
[TBL] [Abstract][Full Text] [Related]
34. Chromen-based TNF-alpha converting enzyme (TACE) inhibitors: design, synthesis, and biological evaluation.
Chun K; Park SK; Kim HM; Choi Y; Kim MH; Park CH; Joe BY; Chun TG; Choi HM; Lee HY; Hong SH; Kim MS; Nam KY; Han G
Bioorg Med Chem; 2008 Jan; 16(1):530-5. PubMed ID: 17936631
[TBL] [Abstract][Full Text] [Related]
35. Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis.
Moss ML; Sklair-Tavron L; Nudelman R
Nat Clin Pract Rheumatol; 2008 Jun; 4(6):300-9. PubMed ID: 18414459
[TBL] [Abstract][Full Text] [Related]
36. The P2/P2' sites affect the substrate cleavage of TNF-α converting enzyme (TACE).
Liu S; Liu S; Wang Y; Liao Z
Mol Immunol; 2014 Nov; 62(1):122-8. PubMed ID: 24980871
[TBL] [Abstract][Full Text] [Related]
37. Studies on novel 2-imidazolidinones and tetrahydropyrimidin-2(1H)-ones as potential TACE inhibitors: design, synthesis, molecular modeling, and preliminary biological evaluation.
DasGupta S; Murumkar PR; Giridhar R; Yadav MR
Bioorg Med Chem; 2009 May; 17(10):3604-17. PubMed ID: 19394232
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of tumor necrosis factor-alpha (TNF-alpha) production and arthritis in the rat by GW3333, a dual inhibitor of TNF-alpha-converting enzyme and matrix metalloproteinases.
Conway JG; Andrews RC; Beaudet B; Bickett DM; Boncek V; Brodie TA; Clark RL; Crumrine RC; Leenitzer MA; McDougald DL; Han B; Hedeen K; Lin P; Milla M; Moss M; Pink H; Rabinowitz MH; Tippin T; Scates PW; Selph J; Stimpson SA; Warner J; Becherer JD
J Pharmacol Exp Ther; 2001 Sep; 298(3):900-8. PubMed ID: 11504783
[TBL] [Abstract][Full Text] [Related]
39. Drug evaluation: apratastat, a novel TACE/MMP inhibitor for rheumatoid arthritis.
Thabet MM; Huizinga TW
Curr Opin Investig Drugs; 2006 Nov; 7(11):1014-9. PubMed ID: 17117591
[TBL] [Abstract][Full Text] [Related]
40. Acetylenic inhibitors of ADAM10 and ADAM17: in silico analysis of potency and selectivity.
Healy EF; Romano P; Mejia M; Lindfors G
J Mol Graph Model; 2010 Nov; 29(3):436-42. PubMed ID: 20863729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
